Korea Steps Up AI Adoption In Drug Discovery, Repositioning And Surveillance
South Korea is stepping up the adoption of artificial intelligence to speed up drug development by selecting discovery, repositioning and smart drug surveillance as three initial focus areas for new AI/big data platforms.
You may also be interested in...
Digital Health Trends: Asia Catching Up But Hurdles Remain
Digital health initiatives are rapidly emerging in Asia amid robust innovation and rising R&D activities in the region, but there are still some hurdles to overcome. An executive from Pfizer talks to Scrip about some of the major trends, opportunities and challenges.
How Can Korea Grab Window Of Opportunity In AI Drug Development?
Participants at a recent policy forum in Seoul stressed the need to secure appropriate technology and expertise, unify government support and draw up a joint cooperation plan between industry and government as key factors in advancing AI-guided new drug development in South Korea.
Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.